PURPOSE: By using data from North Central Cancer Treatment Group Phase III Trial N0147, a randomized adjuvant trial of patients with stage III colon cancer, we assessed the relationship between smoking and cancer outcomes, disease-free survival (DFS), and time to recurrence (TTR), accounting for heterogeneity by patient and tumor characteristics. PATIENTS AND METHODS Before random assignment to infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX) or FOLFOX plus cetuximab, 1,968 participants completed a questionnaire on smoking history and other risk factors. Cox models assessed the association between smoking history and the primary trial outcome of DFS (ie, time to recurrence or death), as well as TTR, adjusting for other clinical and patient factors. The median follow-up was 3.5 years among patients who did not experience events. RESULTS: Compared with never-smokers, ever smokers experienced significantly shorter DFS (3-year DFS proportion: 70% v 74%; hazard ratio [HR], 1.21; 95% CI, 1.02 to 1.42). This association persisted after multivariate adjustment (HR, 1.23; 95% CI, 1.02 to 1.49). There was significant interaction in this association by BRAF mutation status (P = .03): smoking was associated with shorter DFS in patients with BRAF wild-type (HR, 1.36; 95% CI, 1.11 to 1.66) but not BRAF mutated (HR, 0.80; 95% CI, 0.50 to 1.29) colon cancer. Smoking was more strongly associated with poorer DFS in those with KRAS mutated versus KRAS wild-type colon cancer (HR, 1.50 [95% CI, 1.12 to 2.00] v HR, 1.09 [95% CI, 0.85 to 1.39]), although interaction by KRAS mutation status was not statistically significant (P = .07). Associations were comparable in analyses of TTR. CONCLUSION: Overall, smoking was significantly associated with shorter DFS and TTR in patients with colon cancer. These adverse relationships were most evident in patients with BRAF wild-type or KRAS mutated colon cancer.
RCT Entities:
PURPOSE: By using data from North Central Cancer Treatment Group Phase III Trial N0147, a randomized adjuvant trial of patients with stage III colon cancer, we assessed the relationship between smoking and cancer outcomes, disease-free survival (DFS), and time to recurrence (TTR), accounting for heterogeneity by patient and tumor characteristics. PATIENTS AND METHODS Before random assignment to infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX) or FOLFOX plus cetuximab, 1,968 participants completed a questionnaire on smoking history and other risk factors. Cox models assessed the association between smoking history and the primary trial outcome of DFS (ie, time to recurrence or death), as well as TTR, adjusting for other clinical and patient factors. The median follow-up was 3.5 years among patients who did not experience events. RESULTS: Compared with never-smokers, ever smokers experienced significantly shorter DFS (3-year DFS proportion: 70% v 74%; hazard ratio [HR], 1.21; 95% CI, 1.02 to 1.42). This association persisted after multivariate adjustment (HR, 1.23; 95% CI, 1.02 to 1.49). There was significant interaction in this association by BRAF mutation status (P = .03): smoking was associated with shorter DFS in patients with BRAF wild-type (HR, 1.36; 95% CI, 1.11 to 1.66) but not BRAF mutated (HR, 0.80; 95% CI, 0.50 to 1.29) colon cancer. Smoking was more strongly associated with poorer DFS in those with KRAS mutated versus KRAS wild-type colon cancer (HR, 1.50 [95% CI, 1.12 to 2.00] v HR, 1.09 [95% CI, 0.85 to 1.39]), although interaction by KRAS mutation status was not statistically significant (P = .07). Associations were comparable in analyses of TTR. CONCLUSION: Overall, smoking was significantly associated with shorter DFS and TTR in patients with colon cancer. These adverse relationships were most evident in patients with BRAF wild-type or KRAS mutated colon cancer.
Authors: Shuji Ogino; Kaori Shima; Jeffrey A Meyerhardt; Nadine J McCleary; Kimmie Ng; Donna Hollis; Leonard B Saltz; Robert J Mayer; Paul Schaefer; Renaud Whittom; Alexander Hantel; Al B Benson; Donna Spiegelman; Richard M Goldberg; Monica M Bertagnolli; Charles S Fuchs Journal: Clin Cancer Res Date: 2011-12-06 Impact factor: 12.531
Authors: A Fariña-Sarasqueta; G van Lijnschoten; E Moerland; G-J Creemers; V E P P Lemmens; H J T Rutten; A J C van den Brule Journal: Ann Oncol Date: 2010-05-25 Impact factor: 32.976
Authors: Colin H Richards; Jonathan J Platt; John H Anderson; Ruth F McKee; Paul G Horgan; Donald C McMillan Journal: Ann Surg Date: 2011-07 Impact factor: 12.969
Authors: Steven R Alberts; Daniel J Sargent; Suresh Nair; Michelle R Mahoney; Margaret Mooney; Stephen N Thibodeau; Thomas C Smyrk; Frank A Sinicrope; Emily Chan; Sharlene Gill; Morton S Kahlenberg; Anthony F Shields; James T Quesenberry; Thomas A Webb; Gist H Farr; Barbara A Pockaj; Axel Grothey; Richard M Goldberg Journal: JAMA Date: 2012-04-04 Impact factor: 56.272
Authors: N J Samadder; Robert A Vierkant; Lori S Tillmans; Alice H Wang; Charles F Lynch; Kristin E Anderson; Amy J French; Robert W Haile; Lisa J Harnack; John D Potter; Susan L Slager; Thomas C Smyrk; Stephen N Thibodeau; James R Cerhan; Paul J Limburg Journal: Am J Gastroenterol Date: 2012-02-21 Impact factor: 10.864
Authors: David Limsui; Robert A Vierkant; Lori S Tillmans; Alice H Wang; Daniel J Weisenberger; Peter W Laird; Charles F Lynch; Kristin E Anderson; Amy J French; Robert W Haile; Lisa J Harnack; John D Potter; Susan L Slager; Thomas C Smyrk; Stephen N Thibodeau; James R Cerhan; Paul J Limburg Journal: J Natl Cancer Inst Date: 2010-06-29 Impact factor: 13.506
Authors: Matthew F Kalady; Kathryn L Dejulius; Julian A Sanchez; Awad Jarrar; Xiuli Liu; Elena Manilich; Marek Skacel; James M Church Journal: Dis Colon Rectum Date: 2012-02 Impact factor: 4.585
Authors: Garrett M Nash; Mark Gimbel; Alfred M Cohen; Zhao-Shi Zeng; Mackevin I Ndubuisi; Daniel R Nathanson; Jurg Ott; Francis Barany; Philip B Paty Journal: Ann Surg Oncol Date: 2009-10-08 Impact factor: 5.344
Authors: Sheetal Hardikar; Polly A Newcomb; Peter T Campbell; Aung Ko Win; Noralane M Lindor; Daniel D Buchanan; Karen W Makar; Mark A Jenkins; John D Potter; Amanda I Phipps Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-05-14 Impact factor: 4.254
Authors: Amanda I Phipps; Qian Shi; Tyler J Zemla; Efrat Dotan; Sharlene Gill; Richard M Goldberg; Sheetal Hardikar; Balkrishna Jahagirdar; Paul J Limburg; Polly A Newcomb; Anthony Shields; Frank A Sinicrope; Daniel J Sargent; Steven R Alberts Journal: Cancer Epidemiol Biomarkers Prev Date: 2018-03-21 Impact factor: 4.254
Authors: J M Ordóñez-Mena; V Walter; B Schöttker; M Jenab; M G O'Doherty; F Kee; B Bueno-de-Mesquita; P H M Peeters; B H Stricker; R Ruiter; A Hofman; S Söderberg; P Jousilahti; K Kuulasmaa; N D Freedman; T Wilsgaard; A Wolk; L M Nilsson; A Tjønneland; J R Quirós; F J B van Duijnhoven; P D Siersema; P Boffetta; A Trichopoulou; H Brenner Journal: Ann Oncol Date: 2018-02-01 Impact factor: 32.976
Authors: Flurina A M Saner; Alan Herschtal; Brad H Nelson; Anna deFazio; Ellen L Goode; Susan J Ramus; Ahwan Pandey; Jessica A Beach; Sian Fereday; Andrew Berchuck; Stephanie Lheureux; Celeste Leigh Pearce; Paul D Pharoah; Malcolm C Pike; Dale W Garsed; David D L Bowtell Journal: Nat Rev Cancer Date: 2019-06 Impact factor: 60.716